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Context: 5-Reductase 1 and 2 (SRD5A1, SRD5A2) inactivate cortisol to 5-dihydrocortisol in ad-
dition to their role in the generation of DHT. Dutasteride (dual SRD5A1 and SRD5A2 inhibitor) and
finasteride (selective SRD5A2 inhibitor) are commonly prescribed, but their potential metabolic
effects have only recently been identified.
Objective: Our objective was to provide a detailed assessment of the metabolic effects of SRD5A
inhibition and in particular the impact on hepatic lipid metabolism.
Design:We conducted a randomized study in 12 healthy male volunteers with detailed metabolic
phenotyping performed before and after a 3-week treatment with finasteride (5 mg od) or du-
tasteride (0.5 mg od). Hepatic magnetic resonance spectroscopy (MRS) and two-step hyperinsu-
linemic euglycemic clamps incorporating stable isotopes with concomitant adipose tissue micro-
dialysis were used to evaluate carbohydrate and lipid flux. Analysis of the serummetabolomewas
performed using ultra-HPLC-mass spectrometry.
Setting: The studywas performed in theWellcomeTrust Clinical Research Facility,QueenElizabeth
Hospital, Birmingham, United Kingdom.
Main Outcome Measure: Incorporation of hepatic lipid was measured with MRS.
Results: Dutasteride, not finasteride, increased hepatic insulin resistance. Intrahepatic lipid increased
on MRS after dutasteride treatment and was associated with increased rates of de novo lipogenesis.
Adipose tissue lipid mobilization was decreased by dutasteride. Analysis of the serum metabolome
demonstrated that in the fasted state, dutasteride had a significant effect on lipid metabolism.
Conclusions:Dual-SRD5A inhibitionwithdutasteride is associatedwith increased intrahepatic lipid
accumulation. (J Clin Endocrinol Metab 101: 103–113, 2016)
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The worldwide burden of metabolic disease, includingits hepaticmanifestation, nonalcoholic fatty liver dis-
ease (NAFLD), is escalating. NAFLD is associated with
significant morbidity and mortality (1), and there is an
unmet clinical need to understand its pathogenesis to im-
prove treatment. Both glucocorticoids (GCs) and andro-
gens have been implicated in its pathogenesis; circulating
GC excess (Cushing’s syndrome) and T deficiency in men
and excess in women are associated with NAFLD (2–5).
Tissue-specific actions of GCs and androgens (notably
in liver and adipose) are controlled at a prereceptor level
by a series of enzymes that regulate the availability of ste-
roid hormones to bind and activate their cognate recep-
tors. The A-ring reductases include 5-reductase type 1
[SRD5A1], type 2 [SRD5A2], and 5-reductase. SRD5A1
and SRD5A2 reduce 4,5,3-oxosteroid hormones to their
5-reducedmetabolites (6) and are critical in this process.
They inactivate cortisol to 5-dihydrocortisol, which is
subsequently converted in a nonrate-limiting step to 5-
tetrahydrocortisol by 3-hydroxysteroid dehydrogenase.
Additionally, SRD5A1 and SRD5A2 activate T to the
more potent androgen,DHT.Both SRD5A1andSRD5A2
are expressed in human hepatocytes (7), and SRD5A1
alone is expressed in adipocytes (8).
The precise contribution of each isoform toGCmetab-
olism is not clearly defined. Both are able to metabolize
cortisol (but not cortisone). Patients with mutations in
SRD5A2 present with 46XY disorder of sexual differen-
tiation and have been shown to have markedly reduced
5-reduced GC metabolites (9), although the metabolic
phenotype in these patients has not been examined. Cur-
rently patients with functional mutations in SRD5A1 that
compromise enzyme activity have not been identified.
Several cross-sectional and interventional studies have
highlighted a link between 5-reductase and metabolic
phenotype. Enhanced 5-reductase activity is seen in pa-
tients with obesity (10) and polycystic ovary syndrome (11)
correlatingwithmeasuresof insulin resistance (12).Wehave
shownthat5-reductaseactivity is increased inpatientswith
biopsy-proven hepatic steatosis but not in thosewith cirrho-
sis and have proposed that increased 5-reductase activity
mayactasaprotectivemechanismpreventingprogressionof
metabolicphenotypewithin the liver through increased local
clearance of GCs (13). Whereas these studies have been
important in highlighting the relationship between 5-re-
ductase and metabolic phenotype, they have been unable to
resolve whether these observations reflect cause or conse-
quence of disease.Rodent studies have begun to help answer
these questions and suggest that selective deletion of
SRD5A1 may be detrimental (14, 15)
This issue is clinically relevant, not only due to the prev-
alence ofNAFLDand the importance of understanding its
pathogenesis but also with the widespread use of 5-re-
ductase inhibitors in clinical practice. The dual SRD5A1
and SRD5A2 inhibitor, dutasteride, and the selective
SRD5A2 inhibitor, finasteride, are extensively used in the
treatment of benign prostatic hyperplasia, whereby they
decrease local generation of DHT. To date, only a single
study has extensively examined the potential metabolic
impact of 5-reductase inhibition, and although a detri-
mental impact on insulin sensitivity was observed, the im-
pact on the liver remains unclear (16).
We have undertaken a detailed metabolic study to de-
termine the potential effects of 5-reductase inhibition
upon themetabolic phenotype, specifically its potential to
regulate lipid metabolism within the liver and to identify
the mechanisms that may underpin these observations. In
our exploratory study, we used paired hepatic magnetic
resonance, hyperinsulinaemic-euglycaemic clamps incor-
porating stable isotopes, adipose microdialysis, and an
analysis of the serum metabolome to examine the effects
of SRD5A inhibition in detail.
Patients and Methods
Clinical protocol
The clinical protocol received full ethical approval from the
South Birmingham Local Research Ethics Committee (reference
12/WM/0122). Twelve healthy male volunteers (mean age
36.3  4.4 y, body mass index [BMI] 26.6  1.2 kg/m2) were
recruited from local advertisement and provided written in-
formed consent. All were nondiabetic, had not been onGC ther-
apy within the previous 6 months, were normotensive, were not
on any drugs known to impact upon GCmetabolism, were aged
18–65 years, and had a BMI between 20 and 35 kg/m2. The
clinical protocol is summarized below.The decision to recruit 12
healthy volunteers (six per group) was based on a priori power
calculations (for 80% power) extrapolated from published ro-
dent data (14) that identified a 49.2% increase in hepatic lipid
content in SRD5A1 knockout mice. Although there are limita-
tions in extrapolating rodent data into the clinical setting, cal-
culations suggested that at least five volunteers in each group
would be required.
At 5:00 PM, volunteers attended the Wellcome Trust Clinical
Research Facility (Birmingham, United Kingdom), having pro-
vided a 24-hour urinary collection. Total body water was esti-
mated using bioimpedance (model BC418MA; Tanita), and vol-
unteers were given oral 2H2O (3 g/kg total body water in two
divided doses 6:00 and 10:00 PM) followed by drinking water
enriched to 0.4% to determine the rates of hepatic de novo li-
pogenesis (DNL). A standardized meal was provided at 6:00 PM
(carbohydrate 45 g, protein 23 g, and fat 20 g), and after this
point volunteers were fasted until completion of the hyperinsu-
linemic clamp the following day. The following morning a 3T-
magnetic resonance spectroscopy (MRS) of the liver was per-
formed to quantify hepatic lipid content (see below). At 9:00 AM,
an adipose microdialysis catheter (CMAMicrodialysis) was in-
serted under local anesthetic 10 cm lateral to the umbilicus, and
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samples (0.3 L/min) were taken every 30 minutes until com-
pletion of the hyperinsulinemic clamp.
On commencement of the two-step hyperinsulinemic eugly-
cemic clamp, a bolus of U-13C-glucose (CK Gas Ltd) was ad-
ministered (2 mg/kg) over 1 minute followed by a constant in-
fusion (0.02 mg/kg  min). Concurrently, an infusion of 2H5-
glycerol was started (0.1 mol/kg  min) to allow assessment of
whole-body lipolytic rates (rate of endogenous glycerol appear-
ance [Ra glycerol ]). The basal phase continued for 2 hours prior
to commencement of insulin and glucose infusions. Basal steady-
state samples were taken at three time points during the last 30
minutes of the basal phase. At 2 hours, insulin (Actrapid; Novo
Nordisk)was infused at 20mU/m2  minalongside an infusionof
20%glucose enrichedwith U-13C-glucose to 4%. This low-dose
insulin phase continued for 2 hours. For the remainder of the
hyperinsulinemic euglycemic clamp, arterialized blood samples
to measure glucose were taken at 5-minute intervals, and the
glucose infusion rate was adjusted to maintain fasting glycemic
levels. Steady-state sampleswere taken at three time points in the
final30minutesof this low-dose insulinphase.At the completion
of this phase, the insulin infusion rate was increased to 100 mU/
m2  min for the following 2 hours. Steady-state samples were
obtained in this high-dose insulin phase as described above.
Rates of glucose disposal were calculated using a modified ver-
sion of the Steele equations (17, 18). Volunteers were then ran-
domized, but not blinded, to receive treatment with either finas-
teride 5 mg or dutasteride 0.5 mg daily for 3 weeks after which
time all investigations were repeated. Randomization was per-
formed by statisticians who were not part of the investigative
team.Although the primary investigatorswere not blinded to the
treatments, the analysis of key areas including MRS, stable iso-
topes, and serum metabolome was performed by researchers
blinded to the specific treatment.
Biochemical and stable isotope analysis
Liver biochemistry, electrolytes, urea, creatinine, cholesterol,
triglycerides, and full blood counts were measured using stan-
dard laboratory methods (Roche modular system; Roche Ltd).
Cortisol (R&D Systems), insulin (Mercodia), and nonesterified
fatty acids (Zen-Bio) were measured using commercially avail-
able assays according to the manufacturers’ instructions.
Microdialysate samples were collected in microvials and an-
alyzed using a mobile photometric, enzyme-kinetic analyzer
(CMA Iscus Flex) for glucose, pyruvate, lactate. and glycerol.
The enrichment of U-13C-glucose andD5-glycerol (1,1,2,3,3-
D5) in plasma was determined by gas chromatography-mass
spectrometry (model 5973; Agilent Technologies). Deuterium
enrichment of the total body water pool was measured using the
Gasbench II coupled online to a ThermoFinnigan Deltaplus XP
isotope ratio mass spectrometer and the palmitate fraction of
total plasma triglycerides using an automated gas chromatogra-
phy high temperature conversion isotope ratio mass spectrom-
eter ThermoFinnigan Delta Pus XP (ThermoFinnigan) (19).
Calculation of the contribution of de novo
synthesized palmitate to plasma triglyceride
The proportion of endogenous palmitate synthesized de novo
was calculated from the incorporation of 2H (from 2H2O) in the
palmitate present in the plasma triglyceride pool, and this was
calculated using the following formula: fraction  (2H to 1H
ratio in palmitate methyl ester/2H to 1H ratio in water pool)
(34/22), where 34 is the total number of H atoms in palmitate
methyl ester and 22 is the number of water molecules incorpo-
rated into palmitate via DNL (20–22).
MRS determination of hepatic lipid fraction
The method to determine intrahepatic lipid with MRS is in-
cluded in the Supplemental Methods.
Serum and urine steroid metabolite analysis
Serum steroids were measured by liquid chromatography/
mass spectrometry. Briefly, steroids were extracted from serum
(after the addition of the internal standard) via liquid/liquid ex-
traction using tert-methyl butyl ether as described previously
(23). However, to ensure T and DHT could be accurately quan-
tified above the lower limit of quantification (LLOQ), the vol-
ume used for steroid extractionwas increased to 2000L,which
was reconstituted in 125 L before analysis. The tert-methyl
butyl ether layer was removed, evaporated, and reconstituted in
50:50 methanol/water prior to liquid chromatography/mass
spectrometry analysis. Steroids were quantified relative to a cal-
ibration series via tandem mass spectrometry. The calibrators
and quality controls are prepared in-house from steroids (Sigma-
Aldrich) and testedagainst reference standards (ChromSystems).
A Waters Xevo mass spectrometer with an electrospray ioniza-
tion source was used with an attached Acquity liquid chroma-
tography system. Steroids were eluted from a HSS T3, 1.8-m,
1.2-  50-mm column using a methanol/water gradient system
with 0.1% formic acid. The LLOQs for individual steroids were
cortisol 0.7 nmol/L, cortisone 0.7 nmol/L, T 2 nmol/L, andDHT
0.25 nmol/L. The coefficient of variation for all assays was less
than 20% (based on more than six replicate extractions). The
LLOQs quoted above are based on nonconcentrated samples.
Urinary steroids were analyzed by gas chromatography-mass
spectrometry. A detailed description of this methodology has
been published previously (24).
Serum metabolic profiling
Details of the method for the serum metabolic profiling are
included in the Supplemental Data.
Statistical approach
Data are presented as mean  SE unless otherwise stated.
Sample size calculations were based on the primary end point of
change in hepatic lipid content. Additional secondary outcomes
included change in hepatic and peripheral insulin sensitivity and
adipose tissue lipid mobilization. Area under the curve (AUC)
analysis was performed using the trapezoidal method. Paired t
tests were used (or nonparametric equivalents when appropri-
ate) to compare individual variables (eg, MRS and DNL) be-
tween before and after intervention within each patients group.
When variableswere compared between independent groups, ie,
substituting dutasteride for finasteride in one of the two groups
nonpaired tests were used. For analysis of repeated samples (eg,
changes in adipose microdialysis) (either during an individual
investigation or for comparison of the same investigation be-
tween baseline and after 3 wk of the intervention), a two-way,
repeated-measures ANOVAwas used with Bonferroni’s correc-
tion formultiple analyses. All analyses were performed using the
GraphPad statistical software.
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Results
Whole-body insulin sensitivity is unchanged by
treatment with dutasteride or finasteride
Over the 3 weeks of the study, dutasteride and finas-
teride treatment had no effect on anthropometric mea-
surements (Table 1). Dutasteride, but not finasteride, de-
creased systolic blood pressure (BP) (dutasteride: 143 
8.2 mm Hg vs 128  3.6 mm Hg, P  .05; finasteride:
144  8 mm Hg vs 141  7.8 mm Hg, P  .8) with no
effect on diastolic BP or electrolytes. There was no effect
on fasting glucose or insulin levels (Table 1). During the
hyperinsulinemic euglycemic clamp, glucose infusion
rates, either unadjusted or corrected for circulating insulin
levels, were not different before or after dutasteride or
finasteride treatment (Table 2). In addition, glucose dis-
posal (Gd), largely reflecting skeletal muscle insulin sen-
sitivity, did not change in either treatment arm (Table 2
and Figure 1, A and B).
Hepatic insulin sensitivity and lipid accumulation
Hepatic glucose production rate at baseline was not
affected by either dutasteride or finasteride (Table 2 and
Figure 1, C and D). The endogenous glucose production
rate was significantly increased after dutasteride only (du-
tasteride before vs after: 0.61  0.07 mg/kg  min vs
0.92  0.15 mg/kg  min, P  .046; finasteride: 0.71 
0.12 vs 0.54  0.08, P  .18), consistent with increased
hepatic insulin resistance (Figure 1, C and D).
The proton density fat fraction (single echo time) in-
creased in all volunteers treatedwith dutasteride, whereas
in those patients treated with finasteride, only three of the
six had an increase in proton density fat fraction (percent-
age lipid content) (dutasteride before vs after: 0.88 0.35
vs 1.14  0.40, P  .041; finasteride: 3.05  1.58 vs
3.69 2.0, P .35) (Figure 2, A and B). When corrected
for T2 decay, borderline significance was achieved (per-
centage lipid content, dutasteride: 0.58%  0.21% vs
0.75% 0.24%, P .056; finasteride: 2.39% 1.25%
vs 3.08%  1.72%, P  .37).
The relative (percentage) contribution of de novo syn-
thesized palmitate to plasma triglycerides increased in five
of six participants treatedwithdutasteride and inonly two
of six of those randomized to finasteride, but this did not
reach significance (DNL percentage dutasteride before vs
after: 1.21% 0.4% vs. 6.51% 2.7%, P .14; finas-
teride: 1.55% 0.5% vs 1.33% 0.3%, P .65 (Figure
2, C and D, and Table 2). However, in those patients
treated with dutasteride (and not finasteride), the change
Table 1. Demographics, Anthropometric Data, and Fasting Biochemistry in Male Volunteers Before and After
Randomization to 21 Days of Treatment With Either Finasteride (5 mg once a day) or Dutasteride (0.5 mg once a day)
Clinical Variable
Finasteride Dutasteride
Before After Before After
Age, y 36.7  8.2 36.7  8.2 36.0  4.3 36.0  4.3
Weight, kg 98.6  7.5a 98.6  7.4a 76.2  4.4a 76.0  4.0a
BMI, kg/m2 29.6  1.8 29.8  1.8 24.2  1.9 24.1  0.7
Total fat, % 22.6  2.6 23.2  2.7 16.1  1.5 16.5  1.9
Total fat mass, kg 22.9  4.4a 23.5  4.3a 12.4  1.5a 12.5  1.5a
Total fat-free mass, kg 75.7  4.5 75.2  4.5 63.9  3.5 63.5  3.6
SBP, mm Hg 143.5  8.0 140.8  7.8 143.0  8.2b 128.0  3.6b
DBP, mm Hg 87.5  3.5a 84.3  6.9 78.2  2.4a 71.5  5.0
Glucose, mmol/L 4.4  0.2 4.5  0.2 4.4  0.1 4.5  0.1
Insulin, pmol/L 27.1  7.5 29.3  8.6 14.6  4.5 16.7  3.9
HDL cholesterol, mmol/L 1.5  0.1 1.5  0.1 1.4  0.1 1.2  0.2
Total cholesterol, mmol/L 5.5  0.5 5.0  0.7 5.5  0.8 5.5  0.9
Triglycerides, mmol/L 1.1  0.1 0.9  0.1 1.0  0.1 1.5  0.3
AST, U/L (5–43) 21.0  2.0 21.2  2.4 24.7  3.5 23.5  4.1
Bilirubin, mol/L (22) 10.3  1.9 10.4  1.3 17.0  4.2 17.4  5.5
Hemoglobin, g/dL (13.5–18.0) 14.6  0.3b 13.8  0.4b 14.8  0.3b 13.9  0.3b
Cortisol, nmol/L (55–580) 334  37b 196  25a,b 293  26 276  19a
Cortisone, nmol/L (17–97) 78.7  4.3 62.2  4.4a 81.1  4.3 76.9  4.6a
Androstenedione, nmol/L (1.7–7.7) 2.6  0.4 2.9  0.5 2.8  0.4 3.8  0.3
T, nmol/L (10–35) 17.7  2.7 20.4  2.4 14.6  1.0b 22.3  2.1b
DHT, nmol/L (0.3–2.4) 0.9  0.2c 0.2  0.1c 0.7  0.2 0.2  0.0.1
Abbreviations: AST, aspartate aminotransferase; DBP, diastolic BP; HDL, high-density lipoprotein; SBP, systolic BP. Local references are included in
parentheses.
a P  0.05, dutasteride vs finasteride.
b P  .05, before vs after treatment.
c P  .01, before vs after treatment.
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in percentage DNL correlated positively with the change
in hepatic lipid content as measured byMRS (dutasteride:
R2  0.84, P  .0109; finasteride: R2  0.06, P  .6)
(Figure 2E).
Adipose tissue function
Neither dutasteride nor finasteride altered insulin-me-
diated suppression of circulating nonesterified fatty acids
(NEFAs) (Table 2). In addition, Ra glycerol, as a measure
of systemic lipolysis,wasnot changed (Table 2).However,
release of glycerol into sc adipose tissue interstitial fluid
was reduced by dutasteride and not finasteride after the
low-dose insulin infusion (Figure 3 and Table 2). There
was no significant effect of the treatment of interstitial
pyruvate, glucose, or lactate (Table 2). There was a trend
toward decreased interstitial pyruvate release with treat-
ment with dutasteride, which did not reach significance
(Figure 3 and Table 2).
Serum metabolic phenotyping
Dutasteride and not finasteride markedly changed the
serummetabolome in the fasted state. In this nontargeted
Table 2. The Effect of 5-Reductase Inhibition on Glucose and Lipid Metabolism During a Two-Step
Hyperinsulinemic Euglycemic Clamp
Metabolic Variable
Finasteride Dutasteride
Before After Before After
NEFAs, mol/L
Basal 1117  66 1118  53 1190  72 1129  82
Low insulin 708  44 674  13 681  17 679  14
High insulin 654  15 639  7 638  5 658  14
M value, mg/kg  min
Low insulin 3.74  0.77 3.16  0.52 3.23  0.36 3.38  0.51
High insulin 11.11  1.18 10.27  0.69 9.87  0.66 10.23  1.06
Mfi value, mg/kg  min  pmol  L
Low insulin 0.028  0.007 0.027  0.009 0.038  0.012 0.035  0.009
High insulin 0.011  0.002 0.012  0.002 0.015  0.003 0.015  0.003
Ra glucose, mg/kg  min
Basal 0.923  0.125 0.748  0.095 1.134  0.114 1.127  0.139
EGP, mg/kg  min
Low insulin 0.711  0.12 0.540  0.08 0.609  0.07a 0.924  0.15a
Gd, mg/kg  min
Low insulin 2.09  0.58 1.49  0.35 1.90  0.26 2.02  0.40
High insulin 8.30  1.22 7.25  0.85 7.09  0.62 7.84  0.93
Ra glycerol, mg/kg  min
Basal 0.28  0.06 0.21  0.02 0.25  0.02 0.27  0.08
Low insulin 0.20  0.09 0.11  0.03 0.07  0.02 0.07  0.02
High insulin 0.18  0.08 0.13  0.04 0.06  0.01 0.08  0.02
DNL, fractional incorporation of
2H2O into palmitate, %
Basal 1.6  0.5 1.3  0.3 1.2  0.3 6.5  2.7
Adipose microdialysis
Glycerol AUC, mol/L  h
Basal 224  47 259  16 266  24 220  40
Low insulin 151  37 161  22 181  31a 105  22a
High insulin 94  28 86  15 99  19 64  16
Pyruvate AUC, mol/L  h
Basal 54.4  14 57.7  13 61.4  21 37  10
Low insulin 104  19 110  17 134  30 71  11
High insulin 105  9 131  18 141  27 92  16
Lactate AUC, mol/liter  h
Basal 0.96  0.2 0.92  0.1 0.9  0.2 1.3  0.3
Low insulin 1.94  0.3 1.76  0.2 2.2  0.3 1.8  0.3
High insulin 2.67  0.5 2.64  0.3 2.9  0.4 2.2  0.4
Glucose AUC, mmol/liter  h
Basal 3.3  0.6 3.6  0.4 4.4  0.4 4.6  0.5
Low insulin 4.0  0.6 4.0  0.4 4.0  0.5 4.5  0.3
High insulin 4.1  0.7 4.5  0.5 3.3  0.6 5.0  0.4
Abbreviations: EGP, endogenous glucose production. Data are before and after randomization to 21 days of treatment with either finasteride (5
mg once a day) or dutasteride (0.5 mg once a day).
a P  .05, before vs after treatment.
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whole-metabolome approach, results are expressed as
changes of different classes of metabolites rather than in-
dividual metabolites. Dutasteride treatment was associ-
ated with a significant increase in 98 serum metabolites
and a reduction in 25metabolites,whereas finasteride had
amoremodest effect (six increased; five decreased) (Figure
4A). The classes of metabolites changed by dutasteride
were mainly lipids with particular increases in glycero-
phospholipids (Figure 4B).
Both dutasteride and finasteride differentially regu-
lated the response of the serum metabolome to insulin. In
the finasteride arm, prior to treatment, 249 metabolites
were significantly regulated by insulin, and subsequently
only 132 of thesewere regulated by insulin after treatment
with finasteride (P  .05). In the dutasteride arm, 269
unique metabolites were regulated by insulin prior to
treatment. Two hundred sixteenmetabolites continued to
be regulated by insulin after treatment with dutasteride
(P  .06) (Supplemental Figure 1).
Steroid metabolite analysis
Complete 24-hour urinary steroid profile analysis is
presented in Supplemental Table 1. The 5 tetrahydro-
cortisol ratio is an appropriate proxy of SRD5A activity
and does not differ between groups at baseline. As ex-
pected, dutasteride and finasteride both resulted in a sig-
nificant reduction in 5-reduced steroids. Consistent with
decreased adrenal output as a consequence of reduced cor-
tisol clearance, total cortisol metabolites were reduced by
both treatments although this only achieved statistical sig-
nificance in volunteers treated with
dutasteride (Supplemental Table 1).
Serum DHT decreased with both
treatments as anticipated, although
this decrease was statistically signif-
icant only with finasteride.
Discussion
In this study, dutasteride treatment
was associated with hepatic insulin
resistance, hepatic lipid accumula-
tion, and decreased adipose lipid
mobilization without impacting pe-
ripheral insulin sensitivity. Interest-
ingly, both dutasteride and finas-
teride blunted the response of the
serum metabolome to insulin. In the
absence of insulin, dutasteride had a
greater effect than finasteride on the
serummetabolome, notably with re-
gard to lipid intermediates (accept-
ing that circulating cholesterol, triglycerides, and glycerol
did not change). Overall, this may point to a significant
contribution of SRD5A1 to metabolic homeostasis. Both
5-reductase isoforms are expressed in the liver (7),
whereas only SRD5A1 is expressed within adipocytes (8).
It is likely that both isoforms contribute to GC clearance;
however, the additional impact of inhibition of SRD5A1
with dutasteridemay explain themoremarked effects that
we observed on GC metabolites and suppression of total
GC metabolite production. 5-Reductase is critical for
GC clearance and androgen generation, and it remains
plausible that the observations in this study may either
reflect alterations in androgen and/or GC metabolism.
In vitro human and rodent models have demonstrated
that GCs in isolation suppress hepatic and adipose lipo-
genesis.However, alongside insulin, they enhance insulin-
stimulated lipogenesis (19, 25, 26). Consequentially, in-
terventions increasing GC exposure, including 5-
reductase inhibition, may increase adipose and hepatic
lipid accumulation in the presence of insulin. The addi-
tional impact of SRD5A1 inhibition to limit GC clearance
with dutasteride may explain its more marked metabolic
effects. The effects of androgens on lipogenesis in liver and
adipose have not previously been described in detail. T
limits lipid synthesis in rodent hepatocytes (27) and hy-
pogonadism in men is associated with NAFLD (2, 3). The
metabolic fate of T may also be significant because exog-
enously administeredT funneled towardaromatizationby
Figure 1. The effect of 5-reductase inhibition on glucose disposal and glucose production.
Data shown are dutasteride (A and C) and finasteride (B and D) on Gd (A and B) and Ra glucose
(C and D). Open bars, Pretreatment and filled bars, the effect of 3 weeks of drug treatment;
black, dutasteride; shaded, finasteride. *, P  .05 vs pretreatment.
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inhibiting activation to DHT is associated with improved
insulin sensitivity (28).
The findings of this study are supported by observa-
tions in rodent models. There are important distinctions
when extrapolating data from rodents into the clinical
setting. Importantly, rodent livers express only SRD5A1
and not SRD5A2. SRD5A1 knockout mice develop he-
patic steatosis when fed an obesogenic diet, whereas
SRD5A2 knockout mice do not (14, 15). Furthermore, in
a model of hepatic fibrosis, SRD5A1 knockout animals
developedmore severe fibrotic liverdisease (15).Although
the observations in this clinical study may not be as dra-
matic as seen in rodent models, this may not only relate to
differing patterns of SRD5A1 and
SRD5A2 expression, but in our
study, there was still some residual
5-reductase activity as evidenced
by the urinary steroid metabolite
profiles. Indeed, it is possible that the
potency of inhibition may explain
some of the differences observed be-
tween finasteride anddutasteride.The
doses of finasteride and dutasteride
used in this study are those currently
licensed in the United Kingdom, and
therefore, it was believed that using
higher doses in a healthy volunteer
study was not warranted.
Clinical studies have highlighted
the potential role for 5-reductase in
the regulation of metabolic pheno-
type, although there is still debate as
to whether the abnormalities ob-
served represent the cause or conse-
quence of disease. Cross-sectional
studies have demonstrated increas-
ing 5-reductase activity with insu-
lin resistance (12) and increasing ad-
iposity (10) and decreases after
weight loss (29). A recent study ex-
amined the metabolic impact of se-
lective SRD5A inhibition in humans
(16). After a 3-month treatment pe-
riod, they observed inhibition of in-
sulin-mediated suppressionof global
lipolysis by dutasteride as well as a
reduction in peripheral insulin sensi-
tivity, which they suggested might
reflect the role of SRD5A1 within
skeletal muscle. In comparison with
the current study, there are impor-
tant differences to consider in terms
of the duration of treatment, volun-
teer demographics (age, BMI), andmethodology (adipose
microdialysis, doses of insulin used in the clamp studies,
MRS to quantify liver fat before and after treatment) as
well as the analysis of the serum metabolome. Taken to-
gether, these studies would seem to complement each
other and provide evidence as to the potential detrimental
impact of the dual SRD5A1 and SRD5A2 inhibition.
It is important to consider the potential long-term con-
sequences of the observations that we havemade. Hepatic
steatosis is a precursor to progression to more advanced
stages of NAFLD including nonalcoholic steatohepatitis,
and progression rates may be higher than previously
Figure 2. The impact of 5-reductase inhibition on de novo lipogenesis and hepatic lipid
content. Data shown are the effect on dutasteride (A and C) and finasteride (B and D) on hepatic
lipid content percentage as measured by MRS (A and B) and DNL as measured by deuterated
water incorporation into plasma triglyceride palmitate (C and D). Open circles/squares represent
pretreatment and filled circles/squares represent the effect of 3 weeks of drug treatment (circles,
dutasteride; squares, finasteride). *, P  .05 vs pretreatment. The change in rate of DNL is
positively correlated with final liver lipid content after treatment with dutasteride (E) but not
finasteride.
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thought (30). Whereas the changes and absolute amounts
of intrahepatic lipid seen in this study were small, the du-
ration of intervention was short and it remains to be de-
termined whether longer interventions would continue to
cause further lipid accumulation.
Our study has also highlighted potential mechanisms
promoting lipid accumulation. Adipose tissue free fatty
acid delivery is a major contributor
to increased hepatic lipid accumula-
tion (31). Subcutaneous adipose tis-
sue lipolysis was decreased by dutas-
teride (and not finasteride), likely
reflecting the absence of SRD5A2 in
human adipose tissue. This is consis-
tent with increased GC availability,
augmenting the actionof insulin sup-
pressing lipolysis as we have previ-
ously shown in sc (and not omental)
adipose in vitro and in vivo (19). The
differential effects of GCs on sc and
omental adipose tissue may explain
the lack of significant impact on Ra
glycerol. We were unable to assess
hepatocyte function in the sameway;
however, if similarmechanismswere
to operate (as has been shown in
vitro), this would lead to increased
hepatic lipid accumulation (26). It is
likely therefore that the increase in
hepatic steatosis is fueled by in-
creased DNL, which may represent
an important driver to lipid accumu-
lation in specific subgroups of pa-
tients with NAFLD and might be
more relevant than circulating
NEFAs (32).
This effect of dutasteride modu-
lating lipid metabolism is supported
by the changes we saw in the serum
metabolome if not as obvious in the
biochemical parameters (eg, triglyc-
eride, NEFAs, high-density lipopro-
tein, and low-density lipoprotein).
Within the metabolome, dutasteride
treatment was associated with an in-
crease in free fatty acids as well as
increased diacylglycerol and triacyl-
glyercol and a reduction in oxidized
fatty acids (as measured by the
change in hydroxy fatty acids, which
are intermediates in the -oxidation
pathway), suggesting that cellular
metabolism is shifted away from
fatty acid oxidation toward esterification pathways. The
most striking finding from the fasted serum metabolome
was the profound effect dutasteride treatment had on the
lipid classes and in particular the glycerophospholipid
(GPL) class. The finding of dutasteride increasing theGPL
metabolites in tandemwith theobserved increased inMRS
hepatic lipid content complements previously published
Figure 3. The effect of 5-reductase inhibition on sc abdominal adipose tissue. Dutasteride
enhances insulin-mediated suppression of lipolysis in abdominal sc adipose tissue as measured by
adipose interstitial fluid release of glycerol into the microdialysate (A and B). In contrast,
finasteride is without effect (C and D). Similarly, dutasteride decreases insulin-stimulated pyruvate
release into adipose interstitial fluid (E and F), whereas finasteride is without effect (G and H).
Data are presented across the duration of the hyperinsulinemic euglycemic clamp (A, C, E, and
G) and also expressed as AUC for the basal, low insulin, and high insulin phases (B, D, F, and H).
Open circles/squares/bars represent pretreatment and filled circles/squares/bars represent the
effect of 3 weeks of drug treatment (circles or black bars, dutasteride; squares or shaded bars,
finasteride). *, P  .05 vs pretreatment.
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findings of plasma and liver GPL being the greatest lip-
idomic discriminator of liver disease stage (33).
There are limitations of the present study. The treat-
ment intervention was short, and despite randomization,
participants randomized to finasteride had a higher BMI
andhigher baseline levels of intrahepatic lipid, although in
other aspects, the groups were very similar. Importantly,
each subject served as their own control in a paired anal-
ysis.However,wecannot exclude thepossibility thatbase-
line metabolic characteristics might impact on the poten-
tial response to these drugs. Additionally, there were only
sixparticipantswithin eacharmof the stud, although sam-
Figure 4. Serum metabolome analysis in healthy volunteers treated with either dutasteride or finasteride. The total number of metabolites
differentially regulated in the fasting state before and after 3 weeks of a drug intervention is significantly greater in those patients treated with
dutasteride, with a predominant effect on lipid metabolites (A). Classes of lipid metabolites are differentially regulated (either up- or down-
regulated) by dutasteride and finasteride (B).
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ple size estimates had been calculated (see Patients and
Methods). Whereas the data obtained are robust with re-
gard to the impact on hepatic insulin sensitivity, lipid ac-
cumulation and adipose tissue function, the study was
only a short-term intervention and was of insufficient du-
ration to determine changes in body composition. The
potential adverse effects in this healthy volunteer study
were felt not to warrant longer-term administration, but
the detailed effects upon body composition need to be
systematically examined.
In conclusion, dual inhibition of 5-reductase with du-
tasteride appears to convey an adverse metabolic pheno-
type. 5-Reductase inhibitors are widely prescribed, and
the decision to use either finasteride or dutasteride does
not discriminate on the potential metabolic effects. An
increased incidence of heart failure in patients treatedwith
dutasteride has been reported (34), although data remain
conflicting (35), and there is no doubt that further studies
are warranted to determine the long-term metabolic con-
sequence of 5-reductase inhibition.
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